Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro

R. Yamada,K. Steward,G. Ngarmchamnanrith,R. Trinh,S. Khare,R. Sachdev,I. Grewal,S. Morrison,J. Timmerman
DOI: https://doi.org/10.1186/2051-1426-1-S1-P263
2013-05-20
Abstract:
What problem does this paper attempt to address?